Special Issue

Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma

Message from the Guest Editors

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth highest cause of cancer-related deaths worldwide. Potentially curative treatments, such as surgery, radiofrequency or liver transplantation are available for selected patients only, while transarterial chemoembolization or systemic agents are the best treatments for intermediate and advanced stage disease. Indeed, over the last decade, immunotherapy has transformed the treatment of HCC, in particular, following the introduction of immune checkpoint inhibitors (ICPIs). The identification of prognostic and predictive biomarkers to define the best treatment for each patient is urgent. The aim of the special issue is to identify, describe or validate prognostic biomarkers for the diagnosis and survival of HCC based. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: gastroenterology, hepatology, hepatobiliary surgery, transplant surgery, interventional and diagnostic radiology, medical oncology. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Marco Vivarelli

Prof. Dr. Federico Mocchegiani

Dr. Andrea Benedetti Cacciaguerra

Deadline for manuscript submissions

closed (10 July 2023)

MDPI

Cancers

**an Open Access Journal
by MDPI**

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/
cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

MDPI